Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide

Picking up post #13: that is the part I would want checked first.

Semaglutide formulation is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.

An update on my earlier Semaglutide formulation post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.

On the "does it stop working" question: tolerance in the pharmacological sense is not what the withdrawal trials show. What they show is that the effect persists while treatment continues and reverses when it stops, which is a different finding with different implications.

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.

The version of Semaglutide formulation that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.

Agreed, and I will stop repeating the version of this I had been repeating.

Building on post #21 rather than restating it.

Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.

Reading it again, the caveat matters more than the finding.

On formulation: the licensed product is buffered and includes a preservative in the multi-dose presentation. A reconstituted research preparation matches neither, and stability claims made about the first do not carry over to the second.

It is worth checking rather than assuming, which costs nothing.

Adding a small correction to the Semaglutide formulation summary above rather than a disagreement with it. The substance holds; one of the figures is out by a factor that matters.

The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.

Building on post #26 rather than restating it.

Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.

Post #24 put the caveat in the right place and I want to underline it.

Posting my Semaglutide formulation numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a particular answer.

Fair, and the limits you put on it are the part I will remember.

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Scoping that to what I have actually seen rather than what I have read.